In a new study researchers want to learn about people’s attitudes towards a new treatment for lung infections such as pneumonia. They want to understand what makes people feel a certain way and what changes they might need to take to make the treatment more suitable for patients and their doctors/nurses.

It is important that we continue to make new treatments because some treatments may become less effective in some cases. We also need to understand what encourages people to use certain medicines. This can help develop new devices and make them better to use.

The treatment in this study is given along with antibiotics. The treatment is called flagellin. Flagellin is taken in the form of an aerosol which is a cloud of very small droplets of liquid that you breathe in.

What happens if I take part in the study?


If you have a current lung infection or a history of lung infections

If you take part in this study, you will not be given flagellin, the treatment. You will be asked to imagine that you have been given the treatment.  You will be asked to fill in a survey to answer some questions about what you think of the treatment.

The questions will ask about:

  • Your age, gender and what country you live in
  • Your health: how long you have had a lung infection
  • What you think about the treatment

The survey will take around 30-40 minutes.

If you are a doctor/prescriber or a nurse/administrator

If you take part in this study, you will not be administering flagellin, the treatment. You will be asked to imagine that you have given the treatment to a patient.  You will be asked to fill in a survey to answer some questions about what you think of the treatment and how it is administered.

The questions will ask about:

  • Your age, gender and what country you live in
  • Your professional practice: number of years of experience
  • What you think about the treatment

The survey will take around 20-30 minutes.

Take part in the survey


The survey is available in English and French.

If you are a French speaker, you will be offered the opportunity to take part in a group discussion in a second part of the study.

Patients:

English:     https://scalab.cnrs.fr/limesurvey-2.06lts/index.php/568556?lang=en

French:     https://scalab.cnrs.fr/limesurvey-2.06lts/index.php/568556?lang=fr

Healthcare professionals:

English:   https://scalab.cnrs.fr/limesurvey-2.06lts/index.php/626388?lang=en

French:     https://scalab.cnrs.fr/limesurvey-2.06lts/index.php/626388?lang=fr

Sign up to our newsletter